Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1.

AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):205-11. Unique Identifier : AIDSLINE MED/98150874
Gauduin MC; Weir R; Fung MS; Koup RA; The Aaron Diamond AIDS Research Center, The Rockefeller University,; New York, New York 10016, USA.

Abstract: We previously reported that passive transfer of a murine V3-specific monoclonal antibody (BAT123) to hu-PBL-SCID mice challenged with HIV-1LAI confers postexposure protection from infection. The role of the Fc fragment of this antibody as well as the involvement of the complement system in protection were evaluated in vivo. When we compared the postexposure protection offered by BAT123 and CGP 47439, a chimeric form of BAT123 in which the murine Fc domain has been replaced by a human IgG1 Fc domain, CGP 47439 failed to provide postexposure protection against HIV-1LAI despite having similar pharmacokinetics and in vitro neutralizing activity. Furthermore, when hu-PBL-SCID mice were treated with cobra venom factor, which inactivates serum complement activity, the postexposure protective ability of BAT123 was abrogated. These findings suggest that the complement system is involved in the passive protection against HIV-1 infection conferred by the murine monoclonal antibody BAT123 in hu-PBL-SCID mice.
Keywords: *Complement/IMMUNOLOGY *HIV Antibodies/IMMUNOLOGY *HIV Envelope Protein gp120/IMMUNOLOGY *HIV Infections/PREVENTION & CONTROL *HIV-1/IMMUNOLOGY *Immunization, Passive *Peptide Fragments/IMMUNOLOGYKWDcomplement/immunologyKWDhivantibodies/immunologyKWDhivenvelopeproteingp120/immunologyKWDhivinfections/prevention&controlKWDhiv-1/immunologyKWDimmunization,passiveKWDpeptidefragments/immunology
980630
M9861853

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .